a Division of Clinical Nephrology and Rheumatology , Kidney Research Center, Niigata University Graduate School of Medical and Dental Sciences , Niigata , Japan.
b Department of Health and Nutrition Faculty of Human Life Studies , University of Niigata Prefecture , Niigata , Japan.
Amyloid. 2017 Jun;24(2):123-130. doi: 10.1080/13506129.2017.1338565. Epub 2017 Jun 14.
The kidney is a major target organ for systemic amyloidosis, which results in proteinuria and an elevated serum creatinine level. The clinical manifestations and precursor proteins of amyloid A (AA) and light-chain (AL) amyloidosis are different, and the renal damage due to amyloid deposition also seems to differ. The purpose of this study was to clarify haw the difference in clinical features between AA and AL amyloidosis are explained by the difference in the amount and distribution of amyloid deposition in the renal tissues. A total of 119 patients participated: 58 patients with an established diagnosis of AA amyloidosis (AA group) and 61 with AL amyloidosis (AL group). We retrospectively investigated the correlation between clinical data, pathological manifestations, and the area occupied by amyloid in renal biopsy specimens. In most of the renal specimens the percentage area occupied by amyloid was less than 10%. For statistical analyses, the percentage area of amyloid deposition was transformed to a common logarithmic value (Log%amyloid). The results of sex-, age-, and Log%amyloid-adjusted analyses showed that systolic blood pressure (SBP) was higher in the AA group. In terms of renal function parameters, serum creatinine, creatinine clearance (Ccr) and estimated glomerular filtration rate (eGFR) indicated significant renal impairment in the AA group, whereas urinary protein indicated significant renal impairment in the AL group. Pathological examinations revealed amyloid was predominantly deposited at glomerular basement membrane (GBM) and easily transferred to the mesangial area in the AA group, and it was predominantly deposited at in the AL group. The degree of amyloid deposition in the glomerular capillary was significantly more severe in AL group. The frequency of amyloid deposits in extraglomerular mesangium was not significantly different between the two groups, but in AA group, the degree amyloid deposition was significantly more severe, and the deposition pattern in the glomerulus was nodular. Nodular deposition in extraglomerular mesangium leads to renal impairment in AA group. There are significant differences between AA and AL amyloidosis with regard to the renal function, especially in terms of Ccr, eGFR and urinary protein, even after Log10%amyloid was adjusted; showing that these inter-group differences in renal function would not be depend on the amount of renal amyloid deposits. These differences could be explained by the difference in distribution and morphological pattern of amyloid deposition in the renal tissue.
肾脏是全身性淀粉样变性的主要靶器官,可导致蛋白尿和血清肌酐水平升高。淀粉样 A(AA)和轻链(AL)淀粉样变性的临床表现和前体蛋白不同,淀粉样物质沉积所致的肾损伤似乎也不同。本研究旨在阐明肾组织中淀粉样物质沉积量和分布的差异如何解释 AA 和 AL 淀粉样变性之间临床特征的差异。共有 119 名患者参与:58 名确诊为 AA 淀粉样变性(AA 组),61 名 AL 淀粉样变性(AL 组)。我们回顾性研究了临床资料、病理表现与肾活检标本中淀粉样物质所占面积之间的相关性。在大多数肾标本中,淀粉样物质所占面积均小于 10%。为了进行统计学分析,将淀粉样物质沉积面积转换为常用对数(Log%amyloid)。经性别、年龄和 Log%amyloid 校正分析后发现,AA 组患者的收缩压(SBP)较高。在肾功能参数方面,血清肌酐、肌酐清除率(Ccr)和估算肾小球滤过率(eGFR)均提示 AA 组患者肾功能明显受损,而 AL 组患者的尿蛋白则提示肾功能明显受损。病理检查显示,AA 组的淀粉样物质主要沉积在肾小球基底膜(GBM),容易转移到系膜区,而 AL 组则主要沉积在肾小球毛细血管内。AL 组肾小球毛细血管内的淀粉样物质沉积程度明显更严重。两组间肾小球外系膜中淀粉样物质沉积的频率无显著差异,但 AA 组中淀粉样物质沉积的程度明显更严重,沉积模式呈结节状。肾小球外系膜中的结节状沉积导致 AA 组的肾功能受损。AA 和 AL 淀粉样变性之间在肾功能方面存在显著差异,尤其是在 Ccr、eGFR 和尿蛋白方面,即使在调整了 Log10%amyloid 后,这些组间肾功能差异仍存在;表明这些肾功能的组间差异并不取决于肾淀粉样物质的沉积量。这些差异可以用肾组织中淀粉样物质沉积的分布和形态模式的差异来解释。